Clearline Capital LP Acquires 2,522,712 Shares of Heron Therapeutics, Inc. $HRTX

Clearline Capital LP grew its holdings in shares of Heron Therapeutics, Inc. (NASDAQ:HRTX) by 26.0% during the fourth quarter, HoldingsChannel reports. The institutional investor owned 12,235,239 shares of the biotechnology company’s stock after buying an additional 2,522,712 shares during the period. Heron Therapeutics accounts for 0.8% of Clearline Capital LP’s portfolio, making the stock its 26th largest position. Clearline Capital LP owned 0.07% of Heron Therapeutics worth $15,906,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently modified their holdings of the business. Abel Hall LLC bought a new position in shares of Heron Therapeutics during the fourth quarter valued at approximately $60,000. Advisory Services Network LLC grew its stake in shares of Heron Therapeutics by 2,383.4% during the fourth quarter. Advisory Services Network LLC now owns 18,874 shares of the biotechnology company’s stock valued at $25,000 after buying an additional 18,114 shares during the last quarter. Adage Capital Partners GP L.L.C. grew its stake in shares of Heron Therapeutics by 9.2% during the fourth quarter. Adage Capital Partners GP L.L.C. now owns 11,185,325 shares of the biotechnology company’s stock valued at $14,541,000 after buying an additional 946,100 shares during the last quarter. Atom Investors LP bought a new position in shares of Heron Therapeutics during the fourth quarter valued at approximately $63,000. Finally, Squarepoint Ops LLC grew its stake in Heron Therapeutics by 215.2% in the 4th quarter. Squarepoint Ops LLC now owns 677,947 shares of the biotechnology company’s stock worth $881,000 after acquiring an additional 462,840 shares in the last quarter. Institutional investors own 80.01% of the company’s stock.

Heron Therapeutics Stock Performance

Shares of NASDAQ:HRTX opened at $0.39 on Thursday. The firm has a market cap of $73.31 million, a PE ratio of -2.15 and a beta of 1.58. The firm’s 50 day simple moving average is $0.85 and its 200-day simple moving average is $1.07. Heron Therapeutics, Inc. has a one year low of $0.38 and a one year high of $2.30. The company has a debt-to-equity ratio of 17.51, a quick ratio of 1.51 and a current ratio of 2.53.

Heron Therapeutics (NASDAQ:HRTX) last issued its earnings results on Monday, May 11th. The biotechnology company reported ($0.04) EPS for the quarter, missing analysts’ consensus estimates of ($0.03) by ($0.01). Heron Therapeutics had a negative return on equity of 7,747.30% and a negative net margin of 20.53%.The company had revenue of $34.71 million for the quarter, compared to analysts’ expectations of $36.72 million. As a group, equities analysts predict that Heron Therapeutics, Inc. will post -0.09 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on HRTX shares. Zacks Research lowered shares of Heron Therapeutics from a “hold” rating to a “strong sell” rating in a research report on Monday, April 27th. Needham & Company LLC lowered shares of Heron Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, June 2nd. Wall Street Zen lowered shares of Heron Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 16th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Heron Therapeutics in a research report on Tuesday, April 21st. Finally, HC Wainwright reduced their target price on shares of Heron Therapeutics to $2.00 and set a “buy” rating on the stock in a research report on Wednesday, June 3rd. Two analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $2.50.

Heron Therapeutics Profile

Heron Therapeutics, Inc is a commercial-stage biotechnology company focused on developing and commercializing therapies in pain management and supportive care for patients undergoing medical and surgical procedures. The company’s research is dedicated to addressing unmet needs in oncology supportive care and post-operative pain management through innovative drug formulations designed to improve patient outcomes and reduce reliance on opioids.

Heron’s first approved therapy, SUSTOL (granisetron) extended-release injection, received U.S.